Pharmacyclics, Inc.
Investor Relations Department
995 E. Arques Ave.
Sunnyvale, CA 94085
United States

Visit IR website
Sign-up for email alerts

NASDAQ: PCYC [1]	
Last Trade:	84.71
Trade Time:	4:00 PM ET May 21, 2013
Change:	2.85 (3.482%)
Day Range	81.50 - 85.47
52-Week Range	28.77 - 95.85
Volume	766,700
Market Cap. ($M)	6,165.109
Shares Out (M)	72.779

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Pharmacyclics Inc. (Nasdaq: PCYC) is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our pharmaceutical drug development candidates are synthetic small-molecules designed to target key biochemical pathways involved in human diseases with critical unmet needs. Currently, we have three candidates in clinical development and several molecules in preclinical development.... (more)

Stock Performance

Press Releases [View all]

May 1, 2013
Pharmacyclics Reports First Quarter 2013 Results

Apr 24, 2013
Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call

Apr 18, 2013
Pharmacyclics Completes Enrollment of First Phase III Ibrutinib CLL Study - RESONATE™ and Announces Completion of Enrollment of Phase II Ibrutinib MCL Study - SPARK

Apr 11, 2013
Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study

Apr 8, 2013
Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor

Events [View all]

There are no events to display at this time. Please check back later.

Financials [View all]

Feb 26, 2013
Annual Report (10-K)

Apr 9, 2013
Definitive Proxy Statement

May 7, 2013
Quarterly Report (10-Q)

Nov 7, 2012
Quarterly Report (10-Q)

May 10, 2012
Quarterly Report (10-Q)

NASDAQ OMX